Comparative Evaluation of Affibody Molecules for Radionuclide

Aug 16, 2016 - using Affibody molecules, small affinity proteins based on a non- immunoglobulin scaffold. In this study, we compared imaging propertie...
3 downloads 0 Views 1MB Size
Subscriber access provided by United Arab Emirates University | Libraries Deanship

Article

Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX Javad Garousi, Hadis Honarvar, Ken G Andersson, Bogdan Mitran, Anna Orlova, Jos Buijs, John Löfblom, Fredrik Y. Frejd, and Vladimir Tolmachev Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b00502 • Publication Date (Web): 16 Aug 2016 Downloaded from http://pubs.acs.org on September 20, 2016

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 39

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

1 2

Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX

3 4

Javad Garousi ‡, Hadis Honarvar‡, Ken G. Andersson¥, Bogdan Mitran †, Anna Orlova †, Jos Buijs‡,§, John Löfblom¥, Fredrik Y. Frejd‡,║ *,Vladimir Tolmachev1‡.

5 6



Department of Immunology, Genetics and Pathology, Uppsala University, SE-75285 Uppsala, Sweden;

7

¥

8

106 91 Stockholm, Sweden;

9 10

Division of Protein Technology, School of Biotechnology, KTH-Royal Institute of Technology, SE-



Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, SE-751 83 Uppsala, Sweden;

11

§

Ridgeview Instruments AB, SE-74020 Vänge, Sweden.

12



Affibody AB, SE-171 63 Stockholm, Sweden

13 14 15 16 17 18 19 20 21 22 23 24

*Corresponding author: Prof. Fredrik Y. Frejd Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185, Uppsala, Sweden Phone: +46 70 7225189 Fax: +46 18 471 34 32 e-mail: [email protected]

1 ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

25

Abstract

26

Overexpression of the enzyme carbonic anhydrase IX (CAIX) is documented for chronically

27

hypoxic malignant tumors as well as for normoxic renal cell carcinoma. Radionuclide

28

molecular imaging of CAIX would be useful for detection of hypoxic areas in malignant

29

tumors, for patients’ stratification of CAIX-targeted therapies and for discrimination of

30

primary malignant and benign renal tumors. Earlier, we have reported feasibility of in vivo

31

radionuclide based imaging of CAIX expressing tumors using Affibody molecules, small

32

affinity proteins based on a non-immunoglobulin scaffold. In this study, we compared

33

imaging properties of several anti-CAIX Affibody molecules having identical scaffold parts

34

and competing for the same epitope on CAIX, but having different binding paratopes. Four

35

variants were labeled using residualizing 99mTc and non-residualizing 125I labels. All

36

radiolabeled variants demonstrated high-affinity detection of CAIX-expressing cell line SK-

37

RC-52 in vitro and specific accumulation in SK-RC-52 xenografts in vivo. 125I-labeled

38

conjugates demonstrated much lower radioactivity uptake in kidneys but higher radioactivity

39

concentration in blood compared with 99mTc-labed counterparts. Although all variants cleared

40

rapidly from blood and non-specific compartments, there was noticeably difference in their

41

biodistribution. The best variant for imaging of expression of CAIX- in disseminated cancer

42

was 99mTc-(HE)3-ZCAIX:2 providing tumor uptake of 16.3±0.9 %ID/g and tumor-to-blood

43

ratio of 44±7 at 4 h after injection. For primary renal cell carcinoma, the most promising

44

imaging candidate was 125I-ZCAIX:4 providing tumor-kidney ratio of 2.1±0.5. In conclusion,

45

several clones of scaffold proteins should be evaluated to select the best variant for

46

development of an imaging probe with optimal sensitivity for the intended application.

47

48

Key Words: CAIX, Affibody molecule, imaging, radionuclide

2 ACS Paragon Plus Environment

Page 2 of 39

Page 3 of 39

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

49

INTRODUCTION

50

Abnormal expression of cell-surface proteins often accompanies cancerogenesis.

51

Understanding of the role and pattern of such aberrant expression creates a potential for

52

improved diagnostics and treatment of disseminated cancer. Molecular recognition of such

53

abnormally expressed proteins, for example, receptor tyrosine kinases, may be utilized for

54

selective systemic tumor therapy1 and imaging of somatostatin receptor overexpression is

55

applied to stratify patients for radionuclide therapy of neuroendocrine tumors.2 Carbonic

56

anhydrase IX (CAIX) is an aberrantly expressed protein that could potentially be used for

57

improved tumor therapy.3-5

58

CAIX is a cellular membrane-bound enzyme catalyzing the conversion of carbon dioxide to

59

hydrogen carbonate.6 Two extracellular catalytic domains of CAIX form a disulfide bond-

60

stabilized dimer.7 In normal human tissues, CAIX is expressed only in proliferating crypt

61

enterocytes of the intestinal mucosa.8 In hypoxic conditions of a tumor, CAIX is strongly

62

upregulated through the hypoxia inducible factor 1 (HIF-1) cascade and in well oxygenated

63

cells, the expression of HIF-1α is downregulated by the von Hippel-Lindau protein (pVHL).

64

This control is however inactivated in hypoxic cells present in tumors.9 It is worth mentioning

65

that overexpression of CAIX in tumors is not always associated with hypoxia. In clear cell

66

renal carcinomas (CCRC), pVHL is inactivated, which causes high expression of HIF-1α

67

even in normoxic conditions. 10 This is associated with overexpression of CAIX in over 90%

68

of CCRC.11

69

Overexpression of CAIX causes acidification of the tumor microenvironment resulting in

70

reduced cell adhesion, increased motility and migration, and in activated proteases. This

71

increases the potential for tumor invasion and metastasis.9 The acidification of the tumor

72

extracellular space can influence cellular uptake of drugs by favoring weak acids, but reduce

3 ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

73

uptake of weak bases.12 This is in agreement with the results of clinical studies where

74

expression of CAIX in tumors was correlated with chemoresistance of tumors and shorter

75

relapse-free survival of breast cancer patients treated by(neo) adjuvant therapy.13-15 This

76

created a rationale for development of CAIX-targeting anticancer drugs, such as small

77

molecular inhibitors and monoclonal antibodies.16-18 CAIX is considered as a high-priority

78

target by METOXIA, European Collaborative Project aiming at investigation of hypoxic

79

microenvironment of tumors to develop new strategies for improved biomarkers for diagnosis

80

and for more efficient chemo- and radiotherapy.19 The level of tumor-associated CAIX

81

expression, which is determined by immunohistochemistry, correlates strongly with the level

82

of hypoxia in e.g. cervical tumor,20 head and neck carcinoma,21 meningioma, glioblastoma

83

multiforme, comedo type of breast carcinomas and anaplastic ependymoma.22 As hypoxic

84

tumors are radioresistant,23 in vivo detection of CAIX might be a predictive biomarker for

85

resistance to radiation therapy.24 For example, high expression of CAIX is a predictor of local

86

recurrence after radiotherapy of glottic laryngeal carcinoma.25

87

Radionuclide molecular detection of CAIX expression in vivo can be useful for stratifying

88

cancer patients that would most likely respond to emerging CAIX-targeting therapies, and to

89

select subjects with hypoxic tumors, that are not well addressed with conventional radiation

90

therapy. In addition, CAIX-specific probes might be used for imaging primary renal cell

91

carcinomas, where the use of 18F-FDG does not provide sufficient sensitivity due to low

92

glucose utilization.26

93

Current imaging approaches include the use of radiolabeled anti-CAIX monoclonal antibody

94

G250,27 antibody fragments or small molecular CAIX inhibitors, e.g. tertiary

95

benzenesulfonamides.28-30 The use of intact G250 provides high tumor uptake of

96

radionuclides, but a relatively long time (ca. 7 days) is required high contrast (tumor-to-blood

97

ratio of ca. 10).31 The use of smaller fragments enabled to reach a comparable contrast 4 ACS Paragon Plus Environment

Page 4 of 39

Page 5 of 39

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

98

(tumor-to-blood ratio of 8.72 ± 3.45) within 24 hours after injection.28 This suggests that the

99

reduction of the size of protein-based CAIX imaging agents could improve contrast and

100

therefore sensitivity of imaging.

101

The use of non-immunoglobulin scaffold proteins instead of antibody derivatives is an

102

efficient way to create small high-affinity imaging probes.32-33 Scaffold proteins include a

103

robust backbone scaffold providing structural stability and variable amino acids enabling

104

creation of combinatorial libraries. The use of phage, bacterial, ribosome, or yeast display

105

techniques enables selection of small binding proteins having high affinity to desirable

106

molecular targets.34 Affibody molecules are small (6-7 kDa) high affinity protein binders that

107

have been successfully used for development of probes for radionuclide imaging of cancer-

108

related molecular targets, for example, HER2,35-37 EGFR,38 IGF-1R,39 and PDGFRβ.40,41

109

Phase I/II trials with HER2-targeting Affibody molecules have demonstrated that this tracer

110

can provide high contrast imaging in the clinic.42-43 We have recently demonstrated feasibility

111

of radionuclide imaging of CAIX-expression in vivo using the radiolabeled ZCAIX:1

112

Affibody molecule.44 Upon labelling with 99mTc(CO)3, that probe allowed for imaging of

113

CAIX-expressing xenografts 4 h post injection. Tumor-to-blood ratio of 53±1 in a murine

114

model has been achieved at 4 h after injection. This suggested that ZCAIX:1 Affibody

115

molecule could become a useful tool for detection of CAIX expression in vivo. Still, three

116

more clones, ZCAIX:2, ZCAIX:3 and ZCAIX:4 demonstrated similar binding strength during

117

the selection process. Our previous studies have shown that target expression level, size and

118

affinity of a probe are not the only factors influencing contrast of imaging using Affibody

119

molecules. Minor variations in the binding site composition influences off-target interaction

120

of Affibody molecules such as binding to blood proteins and uptake in normal tissues.45-46

121

This may result in an appreciable difference in blood clearance rate and background, affecting

5 ACS Paragon Plus Environment

Molecular Pharmaceutics

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

122

the imaging contrast and therefore sensitivity of the imaging. Thus, evaluation of several

123

candidates might enable selection of a probe with optimal imaging properties.

124

This study aimed at a comparative assessment of the most promising CAIX-binding Affibody

125

molecules to select the best candidate for molecular imaging probes. To perform the

126

evaluation, the residualizing 99mTc(CO)3-HEHEHE and non-residualizing 125I-PIB labels

127

(Figure 1) were used.

128

Figure 1. Schematic presentation of 99mTc(CO)3-HEHEHE and 125I-PIB labels

129 130 131

EXPERIMENTAL SECTION

132

Reagents, equipment and statistics

133

Affibody molecules have been provided by Affibody AB (Solna, Sweden). The CRS kits for

134

production of technetium tricarbonyl were purchased from Center for Radiopharmaceutical

135

sciences (Villigen, Switzerland). An automatic gamma-spectrometer with a NaI (Tl) detector

136

(1480 WIZARDWallac Oy, Turku, Finland) was used for measurement of cell-associate

137

radioactivity and for biodistribution measurements. Formulation of injection solutions was

138

performed using VDC-405 ionization chamber (Veenstra Instruments BV, The Netherlands).

6 ACS Paragon Plus Environment

Page 6 of 39

Page 7 of 39

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

139

Statistical analysis of biological data was performed using GraphPad Prism (version 6.00 for

140

Windows GraphPad Software, San Diego CA) to find any significant differences (p